Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGFRL1 | Q5TC84 | 20/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 16/20 | 0.80 |
| ▸ | OPRK1 | P41145 | 16/20 | 0.80 |
| ▸ | OPRD1 | P41143 | 10/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL853837 | 0.90 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL13221945 | 0.90 | OGFRL1 (0.77) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL853229 | 0.89 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL880328 | 0.88 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL852880 | 0.88 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL880523 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL880397 | 0.87 | OGFRL1 (0.89) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL17561622 | 0.87 | OGFRL1 (0.81) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL852491 | 0.87 | OGFRL1 (1.00) | OGFRL1OPRM1OPRK1OPRD1 | |
| SCHEMBL13221454 | 0.86 | OGFRL1 (0.76) | OGFRL1OPRM1OPRK1OPRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2086958-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | Purdue Pharma LP (US) | 2009-08-12 | — | — | EP | disclosed |
| WO-2009027820-A2 | SUBSTITUTED-QUINOXALINE-TYPE-PIPERIDINE COMPOUNDS AND THE USES THEREOF | PURDUE PHARMA L.P. (DE) | 2009-03-05 | — | — | WO | disclosed |